Elizabeth M. Viglianti

Dr. Elizabeth M. Viglianti

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
JKJacqueline M. Kruser
Jacqueline M. Kruser
DADeepshikha C. Ashana
Deepshikha C. Ashana
KCKatherine R. Courtright
Katherine R. Courtright
EKErin K. Kross
Erin K. Kross
TNThanh H. Neville
Thanh H. Neville
CCChristopher E. Cox
Christopher E. Cox
In critical care, the specific, structured approach to patient care known as a “time-limited trial” has been promoted in the literature to help patients, surrogate decision makers, and clinicians navigate consequential decisions about life-sustaining therapy in the face of uncertainty. Despite promotion of the time-limited trial approach, a lack of consensus about its definition and essential elements prevents optimal clinical use and rigorous evaluation of its impact. The objectives of this American Thoracic Society Workshop Committee were to establish a consensus definition of a time-limited trial in critical care, identify the essential elements for conducting a time-limited trial, and prioritize directions for future work. We achieved these objectives through a structured search of the literature, a modified Delphi process with 100 interdisciplinary and interprofessional stakeholders, and iterative committee discussions. We conclude that a time-limited trial for patients with critical illness is a collaborative plan among clinicians and a patient and/or their surrogate decision makers to use life-sustaining therapy for a defined duration, after which the patient’s response to therapy informs the decision to continue care directed toward recovery, transition to care focused exclusively on comfort, or extend the trial’s duration. The plan’s 16 essential elements follow four sequential phases: consider, plan, support, and reassess. We acknowledge considerable gaps in evidence about the impact of time-limited trials and highlight a concern that if inadequately implemented, time-limited trials may perpetuate unintended harm. Future work is needed to better implement this defined, specific approach to care in practice through a person-centered equity lens and to evaluate its impact on patients, surrogates, and clinicians.

1 August 2018 in The Lancet
Verified
Journal Article
Closed access
EVElizabeth M. Viglianti
Elizabeth M. Viglianti
AOAndrea L Oliverio
Andrea L Oliverio
LMLisa M Meeks
Lisa M Meeks

11 October 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
GIGeorge N. Ioannou
George N. Ioannou
ABAmy S.B. Bohnert
Amy S.B. Bohnert
AOAnn M. O'Hare
Ann M. O'Hare
EBEdward J. Boyko
Edward J. Boyko
MMMatthew L. Maciejewski
Matthew L. Maciejewski
ELEmily R. Locke
Emily R. Locke
This retrospective matched cohort study, which was designed to emulate a target trial of booster vaccination versus no booster, sought to determine mRNA booster vaccine effectiveness against SARS-C... Visual Effectiveness of mRNA COVID-19 Vaccine Boosters in the Omicron Variant Era. This retrospective matched cohort study, which was designed to emulate a target trial of booster vaccinat... Background: The effectiveness of a third mRNA COVID-19 vaccine dose (booster dose) against the Omicron (B.1.1.529) variant is uncertain, especially in older, high-risk populations. Objective: To de...

4 June 2020 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
EVElizabeth M. Viglianti
Elizabeth M. Viglianti
SBSean M. Bagshaw
Sean M. Bagshaw
RBRinaldo Bellomo
Rinaldo Bellomo
JMJoanne McPeake
Joanne McPeake
XWXiao Qing Wang
Xiao Qing Wang
TITheodore J. Iwashyna
Theodore J. Iwashyna

1 November 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
GIGeorge N. Ioannou
George N. Ioannou
KBKristin Berry
Kristin Berry
NRNallakkandi Rajeevan
Nallakkandi Rajeevan
YLYuli Li
Yuli Li
PMPradeep Mutalik
Pradeep Mutalik
KBKristina L. Bajema
Kristina L. Bajema
COVID-19 has been linked to the development of many post-COVID-19 conditions (PCCs) after acute infection. Limited information is available on the effectiveness of oral antivirals used to treat acute COVID-19 in preventing the development of PCCs. To measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing PCCs. Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment. Veterans Health Administration (VHA). Nonhospitalized veterans in VHA care who were at risk for severe COVID-19 and tested positive for SARS-CoV-2 during January through July 2022. Nirmatrelvir-ritonavir treatment for acute COVID-19. Cumulative incidence of 31 potential PCCs at 31 to 180 days after treatment or a matched index date, including cardiac, pulmonary, renal, thromboembolic, gastrointestinal, neurologic, mental health, musculoskeletal, endocrine, and general conditions and symptoms. Eighty-six percent of the participants were male, with a median age of 66 years, and 17.5% were unvaccinated. Baseline characteristics were well balanced between participants treated with nirmatrelvir-ritonavir and matched untreated comparators. No differences were observed between participants treated with nirmatrelvir-ritonavir (n = 9593) and their matched untreated comparators in the incidence of most PCCs examined individually or grouped by organ system, except for lower combined risk for venous thromboembolism and pulmonary embolism (subhazard ratio, 0.65 [95% CI, 0.44 to 0.97]; cumulative incidence difference, -0.29 percentage points [CI, -0.52 to -0.05 percentage points]). Ascertainment of PCCs using International Classification of Diseases, 10th Revision codes may be inaccurate. Evaluation of many outcomes could have resulted in spurious associations with combined thromboembolic events by chance. Out of 31 potential PCCs, only combined thromboembolic events seemed to be reduced by nirmatrelvir-ritonavir. U.S. Department of Veterans Affairs.

13 December 2023 in Chest
Verified
Journal Article
Closed access
JKJacqueline M. Kruser
Jacqueline M. Kruser
NNNandita R. Nadig
Nandita R. Nadig
EVElizabeth M. Viglianti
Elizabeth M. Viglianti
JCJustin T. Clapp
Justin T. Clapp
KSKatharine E. Secunda
Katharine E. Secunda
SHScott D. Halpern
Scott D. Halpern